| Robert Villani, MD | |
|
20 Catamore Blvd, East Providence, RI 02914 | |
| (401) 432-2520 | |
| (401) 432-2457 |
| Full Name | Robert Villani |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 24 Years |
| Location | 20 Catamore Blvd, East Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265466825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 12131 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore University Hospital | Manhasset, NY | Hospital |
| Long Island Jewish Medical Center | New hyde park, NY | Hospital |
| John T Mather Memorial Hospital Of Port Jefferson | Port jefferson, NY | Hospital |
| Plainview Hospital | Plainview, NY | Hospital |
| Ns/lij Hs Southside Hospital | Bay shore, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore - Lij Medical Pc | 3375701568 | 5099 |
| Southside Faculty Medical Affiliates University Faculty Prac | 5698175933 | 158 |
News Archive
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
The neuroscience community is saluting the creation of a "Golden Window" for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi. This is a first for brain imaging, said Shi, a research associate in City College's Institute for Ultrafast Spectroscopy and Lasers, and the biology department.
The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.
The development of cancer is a complex process with a number of different causes. The root problem is loss of control in the cell division process. A fundamental biological process, cell division can be studied in many organisms.
› Verified 8 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
The neuroscience community is saluting the creation of a "Golden Window" for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi. This is a first for brain imaging, said Shi, a research associate in City College's Institute for Ultrafast Spectroscopy and Lasers, and the biology department.
The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.
The development of cancer is a complex process with a number of different causes. The root problem is loss of control in the cell division process. A fundamental biological process, cell division can be studied in many organisms.
› Verified 8 days ago
| Entity Name | Southside Faculty Medical Affiliates University Faculty Prac |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033791058 PECOS PAC ID: 5698175933 Enrollment ID: O20210608003649 |
News Archive
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
The neuroscience community is saluting the creation of a "Golden Window" for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi. This is a first for brain imaging, said Shi, a research associate in City College's Institute for Ultrafast Spectroscopy and Lasers, and the biology department.
The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.
The development of cancer is a complex process with a number of different causes. The root problem is loss of control in the cell division process. A fundamental biological process, cell division can be studied in many organisms.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Villani, MD 20 Catamore Blvd, East Providence, RI 02914 Ph: (401) 432-2520 | Robert Villani, MD 20 Catamore Blvd, East Providence, RI 02914 Ph: (401) 432-2520 |
News Archive
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.
The neuroscience community is saluting the creation of a "Golden Window" for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi. This is a first for brain imaging, said Shi, a research associate in City College's Institute for Ultrafast Spectroscopy and Lasers, and the biology department.
The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.
The development of cancer is a complex process with a number of different causes. The root problem is loss of control in the cell division process. A fundamental biological process, cell division can be studied in many organisms.
› Verified 8 days ago
Gregory Iafrate, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 20 Catamore Blvd, East Providence, RI 02914 Phone: 401-432-2520 Fax: 401-432-2457 | |
Dr. Gary R Marecek, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 20 Catamore Blvd, East Providence, RI 02914 Phone: 401-432-2500 | |
Robert E Lambiase, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 20 Catamore Blvd, East Providence, RI 02914 Phone: 401-432-2520 Fax: 401-432-2457 | |
Sanford L Schatz, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 20 Catamore Blvd, Rhode Island Medical Imaging, East Providence, RI 02914 Phone: 401-432-2520 Fax: 401-432-2457 | |
Robert Lewis Stickle, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 20 Catamore Blvd, East Providence, RI 02914 Phone: 401-432-2520 Fax: 401-432-2457 | |
Joan L Lasser, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 20 Catamore Blvd, Rhode Island Medical Imaging, East Providence, RI 02914 Phone: 401-432-2520 Fax: 401-432-2457 |